If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Mario Santinami is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells

Perotti, V., Baldassari, P., Molla, A., Nicolini, G., Bersani, I., Grazia, G., Benigni, F., Maurichi, A., Santinami, M., Anichini, A. & Mortarini, R., May 30 2019, In : Oncogene. 38, 22, p. 4384-4396 13 p.

Research output: Contribution to journalArticle

Open Access
  • Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

    Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 others, Dummer, R., Kirkwood, J. M. & Long, G. V., May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

    Research output: Contribution to journalArticle

  • Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

    Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 others, Dummer, R., Kirkwood, J. M. & Long, G. V., May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

    Research output: Contribution to journalArticle

  • Reply to E. Hindié and K.R. Hess

    Long, G. V., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E. & 3 others, Kefford, R., Kirkwood, J. M. & Hauschild, A., May 20 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 15, p. 1356-1358 3 p.

    Research output: Contribution to journalArticle

    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

    Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E. & 3 others, Kefford, R., Kirkwood, J. M. & Long, G. V., Oct 22 2018, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. p. JCO1801219

    Research output: Contribution to journalArticle